title: Oxcarbazepine in infants and young children with partial seizures.
abstract: In this open-label study, the safety, tolerability, and pharmacokinetics of oxcarbazepine as monotherapy or adjunctive therapy were studied in infants and young children with partial seizures. In a 30-day treatment phase, oxcarbazepine was titrated from 10 mg/kg/day to 60 mg/kg/day. Blood samples for analysis of the oxcarbazepine metabolite, the 10-monohydroxy derivative (MHD), were obtained at regular intervals. Patients completing the treatment phase entered a 6-month extension phase. Safety and tolerability were assessed throughout the study. Twenty-four patients (mean [range] age, 20.4 [2-45] months) were enrolled. Nineteen (79%) patients completed the treatment phase and, together with one patient who discontinued prematurely during the treatment phase, entered the extension phase. Thirteen of 20 (65%) patients completed the extension phase. The most common adverse events were pyrexia, ear infection, and irritability. Whether patients (n = 23) received enzyme-inducing antiepileptic drugs or not, MHD concentrations were consistent with those predicted from a linear, one-compartment, population-pharmacokinetic model based on a model previously fitted for 3- to 17-year-old children. Oxcarbazepine was safe and well tolerated in infants and young children. The pharmacokinetic profile of MHD was predicted by extension of a model based on older children.
authors.affiliation: Monarch Research Associates, Neuro-Development, Norfolk, VA 23507, USA.
authors.forename: Ralph S
authors.initials: RS
authors.lastname: Northam
authors.forename: Angel W
authors.initials: AW
authors.lastname: Hernandez
authors.forename: Marcia J
authors.initials: MJ
authors.lastname: Litzinger
authors.forename: Daniela N
authors.initials: DN
authors.lastname: Minecan
authors.forename: Tracy A
authors.initials: TA
authors.lastname: Glauser
authors.forename: Surinder
authors.initials: S
authors.lastname: Mangat
authors.forename: Cixuang
authors.initials: C
authors.lastname: Zheng
authors.forename: Claire
authors.initials: C
authors.lastname: Souppart
authors.forename: Yvonne
authors.initials: Y
authors.lastname: Sturm
mesh_terms: D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D002220:Carbamazepine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002675:Child, Preschool; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D000078330:Oxcarbazepine; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D002220:Carbamazepine; D000078330:Oxcarbazepine